Effect of Oral Adenosine-triphosphate (ATP) on Human Muscle Performance

NCT ID: NCT01141504

Last Updated: 2012-01-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adenosine-triphosphate (ATP) serves as the sole energy source for muscle contraction. Therefore human performance of brief maximal exercise is limited, in part, by the availability of ATP to the contracting muscle. Because muscle ATP storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of ATP may have a positive impact on repeated muscle contractions. The current study will test the hypothesis that increasing ATP availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date we have studied 10 subjects who have followed through with all 3 of the original interventions (Placebo, 250 mg PeakATP/d and 400 mg PeakATP/d). Currently we have received approval and are expanding the study with 5 additional subjects who will receive the Placebo, 400 mg PeakATP/d and the 400 mg PealATP/d plus proprietary blend interventions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Oral placebo capsules similar in color and size to the intervention

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo capsules that are comparable in size and color to the active comparator for blinding purposes

PeakATP 250

Oral supplement capsules containing 250 mg/day of PeakATP

Group Type ACTIVE_COMPARATOR

PeakATP 250

Intervention Type DIETARY_SUPPLEMENT

The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day

PeakATP 400

Oral supplement capsules containing 400 mg/day of PeakATP

Group Type ACTIVE_COMPARATOR

PeakATP 400

Intervention Type DIETARY_SUPPLEMENT

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day

PeakATP 400 plus proprietary blend

Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend

Group Type ACTIVE_COMPARATOR

PeakATP 400 plus proprietary blend

Intervention Type DIETARY_SUPPLEMENT

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PeakATP 250

The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo capsules that are comparable in size and color to the active comparator for blinding purposes

Intervention Type DIETARY_SUPPLEMENT

PeakATP 400

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day

Intervention Type DIETARY_SUPPLEMENT

PeakATP 400 plus proprietary blend

The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No major medical conditions;
* Able to perform fatigue testing procedures;
* Not currently taking prescription medications;
* Not currently taking dietary supplements (a daily multi-vitamin not exceeding RDA is permitted)

Exclusion Criteria

* Major medical condition affecting metabolism or general function;
* Not able to perform fatigue testing;
* Taking prescription medications;
* Taking a dietary supplement other than a multi-vitamin not exceeding RDA
Minimum Eligible Age

20 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Iowa State University

OTHER

Sponsor Role collaborator

Metabolic Technologies Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John A Rathmacher, PhD

Role: PRINCIPAL_INVESTIGATOR

Metabolic Technologies Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Iowa State University

Ames, Iowa, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MTI2010-CS01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Carbohydrate Mouth-rinse
NCT01527266 UNKNOWN NA